U.S. Compounding, Inc. (USC) is a subsidiary of Adamis and is registered as a drug compounding
outsourcing facility under Section 503B of the U.S. Food, Drug & Cosmetic Act and the U.S. Drug
Quality and Security Act. USC provides prescription compounded medications, including compounded
sterile preparations, and nonsterile compounds to patients, physician clinics, hospitals, surgery centers
and other clients throughout most of the United States. USC’s product offerings include, among others,
corticosteroids, hospital outsourcing products, sterile injectables, and topical compounds.
USC’s compounded formulations in many circumstances are offered as therapeutic alternatives to
drugs approved by the U.S. Food and Drug Administration, or the FDA. USC prepares and provides a
broad range of customized stock keeping units to meet the individual requirements of customers
located throughout most of the United States. USC also provides certain veterinary pharmaceutical
products for animals.